KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vertex Pharmaceuticals (VRTX) Short term Debt (2016)

Vertex Pharmaceuticals (VRTX) has 6 years of Short term Debt data on record, last reported at $300.0 million in Q4 2016.

  • For Q4 2016, Short term Debt changed N/A year-over-year to $300.0 million; the TTM value through Dec 2016 reached $300.0 million, changed N/A, while the annual FY2016 figure was $300.0 million, N/A changed from the prior year.
  • Short term Debt reached $300.0 million in Q4 2016 per VRTX's latest filing, up from $297.8 million in the prior quarter.
  • Across five years, Short term Debt topped out at $300.0 million in Q4 2016 and bottomed at $14.2 million in Q4 2014.
  • Average Short term Debt over 3 years is $150.2 million, with a median of $146.3 million recorded in 2016.
  • The widest YoY moves for Short term Debt: up 416.82% in 2016, down 412.68% in 2016.
  • A 3-year view of Short term Debt shows it stood at $14.2 million in 2014, then soared by 201.8% to $42.9 million in 2015, then soared by 599.74% to $300.0 million in 2016.
  • Per Business Quant database, its latest 3 readings for Short term Debt were $300.0 million in Q4 2016, $297.8 million in Q3 2016, and $221.6 million in Q2 2016.